Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-2)

NCT05255991 is registered in ClinicalTrials.gov with United Therapeutics as lead sponsor.

NCT NCT05255991
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05255991 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-2)
Lead sponsor
United Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
October 4, 2022
Completion date
June 30, 2025
Enrollment
597 (actual)
Sites
108

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic pulmonary fibrosis, interstitial lung disease